Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: ICH S5 Reproductive Toxicity Testing Guidelines | Statement: [ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, relatedTo, ICH S5 Reproductive Toxicity Testing Guidelines]

Target entity: ICH S5 Reproductive Toxicity Testing Guidelines
Context triple: [ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, relatedTo, ICH S5 Reproductive Toxicity Testing Guidelines]

• A. ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
  ICH M3(R2) is an international guideline that harmonizes requirements for nonclinical safety studies needed to support the initiation and progression of human clinical trials and the marketing authorization of pharmaceuticals.
• B. Experimental Toxicology and ZEBET
  Experimental Toxicology and ZEBET is a specialized section of Germany’s Federal Institute for Risk Assessment focused on experimental toxicology and the development and promotion of alternative methods to animal testing.
• C. ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
  ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals is an international guideline that outlines the nonclinical safety testing requirements for biotechnological products such as therapeutic proteins and monoclonal antibodies to support their clinical development and marketing authorization.
• D. ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
  ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals is an international regulatory guideline that outlines the nonclinical safety studies needed to support the development and approval of anticancer drugs in humans.
• E. Toxicology in the 21st Century program
  The Toxicology in the 21st Century program is a U.S. research initiative that uses modern high-throughput and computational methods to improve the prediction of chemical toxicity and reduce reliance on traditional animal testing.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"

Entity: ICH S5 Reproductive Toxicity Testing Guidelines
Triple: [ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, relatedTo, ICH S5 Reproductive Toxicity Testing Guidelines]

The ICH S5 Reproductive Toxicity Testing Guidelines are international standards that outline how to evaluate the potential effects of pharmaceuticals on fertility, embryo-fetal development, and pre- and postnatal development to support safe drug use in humans.

Target entity: ICH S5 Reproductive Toxicity Testing Guidelines
Target entity description: The ICH S5 Reproductive Toxicity Testing Guidelines are international standards that outline how to evaluate the potential effects of pharmaceuticals on fertility, embryo-fetal development, and pre- and postnatal development to support safe drug use in humans.

• A. ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
  ICH M3(R2) is an international guideline that harmonizes requirements for nonclinical safety studies needed to support the initiation and progression of human clinical trials and the marketing authorization of pharmaceuticals.
• B. Experimental Toxicology and ZEBET
  Experimental Toxicology and ZEBET is a specialized section of Germany’s Federal Institute for Risk Assessment focused on experimental toxicology and the development and promotion of alternative methods to animal testing.
• C. ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
  ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals is an international guideline that outlines the nonclinical safety testing requirements for biotechnological products such as therapeutic proteins and monoclonal antibodies to support their clinical development and marketing authorization.
• D. ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
  ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals is an international regulatory guideline that outlines the nonclinical safety studies needed to support the development and approval of anticancer drugs in humans.
• E. Toxicology in the 21st Century program
  The Toxicology in the 21st Century program is a U.S. research initiative that uses modern high-throughput and computational methods to improve the prediction of chemical toxicity and reduce reliance on traditional animal testing.
• F. None of above. chosen